GAG Polymerase Engineering Service at CD BioGlyco

CD BioGlyco is equipped with a dedicated research team to develop the production of viral vectors. We are committed to providing gene function research, vector development, and efficacy studies for basic gene therapy research.

• Retroviral Packaging Service
  Retrovirus is an RNA virus with a long terminal repeat sequence (LTR) at both ends. It has three genes in its genome: Gag (encoding the core protein of the virus), Pol (encoding the reverse transcriptase), and Env (encoding the periplasmic glycoprotein of the virus). Retroviruses are suitable for many stem cell-related research, such as neural stem cell research and hematopoietic stem cell research. When applied in vivo, retroviruses are suitable for work on adult neonatal neurons or glial precursor cells. We provide murine stem cell virus and murine leukemia virus retrovirus services. We continuously optimize the packaging process of retroviruses in terms of viral purity, titer, activity, and homogeneity. We will construct different transfer vectors according to customers' needs, including overexpression, Knockdown, and interference.

Fig.1 Flowchart of retrovirus service. (CD BioGlyco)

• Human Immunodeficiency Virus (HIV) Vaccine Development Service
  Live viral vector vaccines express target proteins in vivo and thus have good immunogenicity. Live vectors themselves are used as immune adjuvants to enhance the effect of cellular and humoral immunity. The structural gene of the HIV-1 virus, GAG polymerase (Gag-Pol), is rich in cytotoxic T lymphocyte (CTL) epitopes and T helper epitopes. DNA and viral vector vaccines are developed by using it as the target protein. The development of DNA and viral vector vaccines using GAG-Pol as the target protein has become a hotspot of HIV vaccine research. Upon request, we will use various technologies for Gene Editing to modify the HIV Gag-Pol gene and construct recombinant viral vector vaccines. We will also complete downstream-related experiments, such as testing its antigen expression, antigenicity, immunogenicity, etc. The immunogenicity of the recombinant viral vector vaccine will be verified by examining the effect of the recombinant viral vector vaccine on the humoral immune response of mice. We aim to support the development of novel immunological regimens for HIV vaccines.

Applications

• As an efficient expression system, retroviral expression vectors have great potential for application in gene therapy and biopharmaceuticals.
• Retroviral expression vectors play an important role in studying the mechanisms of cancer formation, invasion, and metastasis, and help to find new targets for cancer treatment.
• The technologies for GAG polymerase gene editing are used in the construction of stable cell lines, and experiments related to the detection of immune response at the cellular and animal levels.

Advantages

• We provide a one-stop service from DNA synthesis to retroviral production.
• Our packaging systems have a wide range of affinities. They are modified to facilitate high-level expression of target genes in cells.
• Our packaging system acts on a wide range of hosts and transduces cells derived from conventional mammals such as mice and rats.

CD BioGlyco has a complete range of equipment for experimental viral vector packaging, molecular biology, animal testing, etc. We are constantly optimizing our gene-editing technology by focusing on our clients. In addition, we also provide Fucosyltransferase Engineering Service and Mannosyltransferase Engineering Service. Please feel free to contact us for more information. We will answer your questions immediately.

Reference:

1. Garcia-Miranda, P.; et al. The stability of HIV frameshift site RNA correlates with frameshift efficiency and decreased virus infectivity. Journal of Virology. 2016, 90(15): 6906-6917.